OTCMKTS:ASPHF Ascentage Pharma Group International (ASPHF) Stock Price, News & Analysis $4.53 0.00 (0.00%) As of 07/31/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Ascentage Pharma Group International Stock (OTCMKTS:ASPHF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ASPHF alerts:Sign Up Key Stats Today's Range$4.53▼$4.5350-Day Range$4.53▼$5.0452-Week Range$4.53▼$5.05VolumeN/AAverage Volume100 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ascentage Pharma Group International (OTCMKTS:ASPHF) is a clinical-stage biopharmaceutical company headquartered in Beijing, China, with a strategic presence in the United States. The company focuses on the discovery and development of targeted small-molecule therapies that modulate programmed cell death, leveraging a deep understanding of the Bcl-2 family of proteins. Ascentage’s core activities center on the research and development of apoptosis regulators, including both Bcl-2 selective and dual Bcl-2/Bcl-xL inhibitors. Its diverse pipeline comprises several compounds in various stages of clinical and preclinical evaluation, addressing both hematological malignancies and solid tumors. The company’s R&D operations integrate proprietary chemistry platforms with translational biology to accelerate the progression of novel candidates through global regulatory pathways. The company serves markets across Greater China, North America, and Singapore, collaborating with contract research organizations and academic institutions worldwide. Through partnerships and strategic alliances, Ascentage aims to expand its clinical footprint and optimize trial execution, particularly for oncology indications with significant unmet medical needs. Founded in 2010 by a team of life science researchers, Ascentage has grown under a management team of industry veterans with extensive experience in drug discovery and development. This leadership combines academic insights with pharmaceutical expertise to drive innovation and establish the company as a global player in oncology therapeutics.AI Generated. May Contain Errors. Read More Receive ASPHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascentage Pharma Group International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASPHF Stock News HeadlinesAscentage Pharma Strengthens Global Commercial Push With Senior Executive HiresAugust 2 at 7:51 PM | tipranks.comAscentage Pharma Advances Phase III Oral Combo in CLL: What Investors Should WatchJuly 28, 2026 | tipranks.comHe knows what's coming this yearAn investor famous for predicting the 2008 housing crash has quietly built a $185 million stake in a small American gold company since 2016. In June, weeks after a federal board approved a roughly $3 billion loan to the company, he added another $100 million at $13.20 a share, controlling about a third of the business. Final loan documents are expected in the second half of this year, while shares still trade under $20.August 4 at 1:00 AM | Behind the Markets (Ad)Ascentage Pharma CEO Dajun Yang Ranked Among Top Small-Molecule Leaders in 2026 Power ListJuly 27, 2026 | tipranks.comAscentage Pharma Sets Up US$200 Million Nasdaq ATM Offering Following SEC Shelf FilingJuly 20, 2026 | tipranks.comAscentage Pharma Sets Up $200 Million Nasdaq ATM Offering ProgramJuly 19, 2026 | tipranks.comAscentage Pharma Corrects AGM Date Underpinning Equity Incentive MandateJuly 13, 2026 | tipranks.comAscentage Pharma Corrects AGM Date for Share Incentive Scheme MandateJuly 12, 2026 | tipranks.comSee More Headlines ASPHF Stock Analysis - Frequently Asked Questions How have ASPHF shares performed this year? Ascentage Pharma Group International's stock was trading at $8.48 at the start of the year. Since then, ASPHF stock has decreased by 46.6% and is now trading at $4.53. How do I buy shares of Ascentage Pharma Group International? Shares of ASPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/04/2026Next Earnings (Estimated)8/26/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:ASPHF CIKN/A Webwww.ascentagepharma.com Phone86-512-8555-7777FaxN/AEmployees565Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (OTCMKTS:ASPHF) was last updated on 8/4/2026 by MarketBeat.com Staff. From Our Partners"Second Wave” Hitting Iran Soon? Wall Street Issues WarningAnalysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...Chaikin Analytics | SponsoredFree Stock Pick: The Company First in Line for America’s New Super FuelThe U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredNow that SpaceX is public, buy this ticker (no, not SpaceX or Tesla)The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was...Brownstone Research | SponsoredThis loan shouldn't be possibleOn May 21, 2026, a federal board unanimously approved a roughly 3 billion dollar loan to a single American min...Behind the Markets | Sponsored70% of the Fortune 100 depend on this mystery AI stockSeventy percent of the Fortune 100 already rely on one company's AI cybersecurity platform, which combines mor...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.